• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MAIA

    MAIA Biotechnology Inc.

    Subscribe to $MAIA
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2022

    Exchange: AMEX

    Recent Analyst Ratings for MAIA Biotechnology Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    MAIA Biotechnology Inc. SEC Filings

    See more
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/25/25 9:55:20 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/24/25 9:15:10 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/18/25 9:25:54 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/17/25 4:10:24 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by MAIA Biotechnology Inc.

      D - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/11/25 4:15:32 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/5/25 4:05:42 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/2/25 6:06:48 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      5/28/25 9:00:41 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      5/23/25 9:22:59 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      5/22/25 4:15:34 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MAIA Biotechnology Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smith Stan bought $50,000 worth of shares (33,333 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      6/5/25 4:42:27 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Guerrero Ramiro bought $30,000 worth of shares (20,000 units at $1.50), increasing direct ownership by 4% to 588,218 units (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/12/25 4:14:02 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Smith Stan bought $99,999 worth of shares (66,666 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/12/25 4:12:43 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Guerrero Ramiro bought $50,000 worth of shares (33,333 units at $1.50), increasing direct ownership by 6% to 568,218 units (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      3/5/25 4:42:20 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Smith Stan bought $37,500 worth of shares (25,000 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      3/5/25 4:40:57 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Smith Stan bought $75,000 worth of shares (50,000 units at $1.50) (SEC Form 4)

      4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      3/5/25 4:39:20 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Guerrero Ramiro bought $110,000 worth of shares (73,333 units at $1.50), increasing direct ownership by 16% to 534,885 units (SEC Form 4)

      4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      3/5/25 4:37:22 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Guerrero Ramiro bought $110,000 worth of shares (73,333 units at $1.50), increasing direct ownership by 16% to 534,885 units (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      2/25/25 4:11:24 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Smith Stan bought $75,000 worth of shares (50,000 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      2/25/25 4:10:22 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Smith Stan bought $46,800 worth of shares (25,000 units at $1.87) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      12/13/24 5:17:59 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MAIA Biotechnology Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

      MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies (FEBS) 2025 Congress, hosted by the Turkish Biochemical Society, to be held July 5-9, 2025, in Istanbul, Turkey. The poster presentations highlight MAIA's lead telomere-targeting agent and next-generation treatments. The first presentation will be delivered by MAIA Scientific Advisory Board member, Z. Gunnur Dikmen, M.D., Ph.D., Hacettepe University, Faculty of Medicine, Department of Biochemistry in Ankara, Turkey. Poster

      7/1/25 9:00:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

      Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

      6/24/25 8:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

      Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA's telomere-targeting agent ateganosine (THIO), sequenced with Roche's checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers. "In preclinical studies, ateganosine was found to be highly synergistic and effective in combination w

      6/18/25 9:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology to Present at BIO International Convention 2025

      MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its participation in the upcoming BIO (Biotechnology Innovation Organization) International Convention 2025 taking place June 16-19, 2025, in Boston, Massachusetts. MAIA Chairman and CEO Vlad Vitoc, MD, MBA will deliver a presentation featuring the latest findings from the Company's THIO-101 Phase 2 clinical trial evaluating ateganosine (THIO) sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC). Ateganosine is a small molecule telomere-targeting anticancer agent that

      6/10/25 8:46:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

      MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial response (PR) was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine (THIO), sequenced with Regeneron's immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. A partial response is defined as a decrease in tumor size of at least 30%. "The patient remained on treatment and we observed stable disease for more than twenty mo

      6/5/25 11:10:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

      Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron's immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. As of May 15, 2025, third line (3L) data showed median overall survival (OS) of 17.8 months fo

      6/5/25 8:04:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces Private Placement of Approximately $669,500

      MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 446,332 shares of common stock at a purchase price of $1.50 per share, in a private placement to accredited investors and a Company director. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $1.71 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to customar

      5/27/25 4:30:00 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

      MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3, 2025, in Chicago, Illinois. The poster is scheduled for presentation on May 31, 2025, from 01:30pm to 04:30pm CDT in the Lung Cancer track. "We continue to believe that our telomere targeting agent ateganosine (THIO) could become a best-in-class anticancer treatment with the potential to challenge the standard

      5/15/25 11:05:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces Director Participation in Recent Private Placement

      MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that two of the Company's independent directors, Stan V. Smith, Ph.D. and Ramiro Guerrero, JD, LL.M., purchased common stock and warrants in the Company's private placement offering which closed on May 8, 2025. Gross proceeds from the offering across all investors totaled $1.08 million. Dr. Smith purchased a total of 66,666 shares and 66,666 warrants for an aggregate purchase price of approximately $100,000. Mr. Guerrero purchased a total of 20,000 shares and 20,000 warrants for an aggregate purchase price of $30

      5/14/25 10:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

      This is a correction of the announcement. The initial exercise date and term of the warrants purchased in the private placement have been corrected to one year following issuance and have a term of six years from the initial issuance date. All other aspects of the announcement remain the same. MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 719,999 shares of common stock at a purchase price of $1.50 per share, in a private placement to accredited investors and certain Company dir

      5/5/25 11:45:00 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MAIA Biotechnology Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Guerrero Ramiro

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:17:45 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chaouki Steven M

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:16:50 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Louie Ngar Yee

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:16:10 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith Stan

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:14:56 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Luput Cristian

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:13:57 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Theagene Jean-Manasse

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:13:00 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Smith Stan bought $50,000 worth of shares (33,333 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      6/5/25 4:42:27 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Vitoc Vlad

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/16/25 4:15:26 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Gryaznov Sergei

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/16/25 4:14:36 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Head of Finance Himmelreich Jeffrey C

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/16/25 4:13:34 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MAIA Biotechnology Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by MAIA Biotechnology Inc.

      SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 6:16:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MAIA Biotechnology Inc.

      SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 5:12:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MAIA Biotechnology Inc.

      SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 5:10:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MAIA Biotechnology Inc.

      SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

      2/14/23 12:00:03 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MAIA Biotechnology Inc.

      SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

      2/14/23 11:37:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MAIA Biotechnology Inc.

      SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

      2/14/23 11:35:59 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    MAIA Biotechnology Inc. Leadership Updates

    Live Leadership Updates

    See more
    • MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

      Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

      6/24/25 8:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

      Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

      3/25/25 8:46:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

      Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire) Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hos

      3/21/24 3:00:00 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

      New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB). With over 20 years of academic and biopharmaceutical industry experience, Dr. Vezan is a highly regarded leader in drug development of novel therapeutic modalities, including cell and gene therapies, and played a pivotal role in the devel

      2/27/24 10:30:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care